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Human immunodeficiency virus (HIV)-specific CD8+ T cells play a critical role in contain-
ing HIV replication and delaying disease progression. However, HIV-specific CD8+ T cells 
become progressively more “exhausted” as chronic HIV infection proceeds. Symptoms 
of T cell exhaustion range from expression of inhibitory receptors and selective loss of 
cytokine production capacity through reduced proliferative potential, impaired differenti-
ation into effector cells and increased susceptibility to apoptosis. While effective combi-
nation antiretroviral therapy (cART) durably reduces HIV viremia to undetectable levels, 
this alone does not restore the full pluripotency of HIV-specific CD8+ T cells. In a number 
of studies, a subset of peptide epitope variants categorized as heteroclitic, restimulated 
more potent cellular immune responses in vitro than did the native, immunizing peptides 
themselves. This property of heteroclitic peptides has been exploited in experimental 
cancer and chronic viral infection models to promote clearance of transformed cells and 
persistent viruses. In this review, we consider the possibility that heteroclitic peptides 
could improve the efficacy of therapeutic vaccines as part of HIV immunotherapy or 
eradication strategies. We review literature on heteroclitic peptides and illustrate their 
potential to beneficially modulate the nature of HIV-specific T cell responses toward 
those found in the small minority of HIV-infected, aviremic cART-naïve persons termed 
elite controllers or long-term non-progressors. Our review suggests that the efficacy of 
HIV vaccines could be improved by identification, testing, and incorporation of hetero-
clitic variants of native HIV peptide epitopes.
Keywords: heteroclitic peptide, CD8+ T cell, therapeutic vaccines, Hiv, epitope
introduction
Sequence variants of native or reference peptide are commonly referred to as analog peptides, 
mimotopes, altered peptide ligands (APL), or variant peptides. Heteroclitic peptides are a subset of 
these sequence variants that stimulate stronger T cell responses than the native epitope or reference 
sequence used for primary immunization (1, 2). Amino acid (aa) substitutions made in the peptide 
sequence of heteroclitic peptides presumably increase peptide antigenicity and immunogenicity by 
enhancing peptide-binding affinity for human histocompatibility-linked leukocyte antigens (HLA) 
and/or improving T cell receptor (TCR) recognition of the bound peptide (3–5). Given that thymic 
T cell positive selection is ultimately based on moderate affinity TCR binding to self-peptides pre-
sented on cortical epithelial cells, the concept of reference or native epitopes in an immune response 
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arising against a foreign pathogen is purely contextual, from a 
T cell repertoire perspective. The reactivity of any individual T 
cell clone is selective not for one particular peptide, but for an 
entire series of related peptides that elevate TCR interaction avid-
ity relative to that manifest through interaction with the original 
self-peptide. Although it can be addressed experimentally with 
sequence variants, where any particular reference, native or wild-
type (WT) foreign peptide recognized by host T cells sits among 
the virtual series of peptides enabled for recognition through the 
original selection by a self-peptide, is unknown. Thus, there is a 
clear theoretical rationale suggesting that sequence variants can 
readily be constructed to mediate enhanced immune recognition 
compared to empirically defined reference, native or WT foreign 
peptides.
The finding that T cells from mice immunized with pigeon 
cytochrome c made stronger proliferative responses in  vitro 
against tobacco hornworm moth cytochrome c than against 
pigeon cytochrome c itself was the first documented example of 
a heteroclitic peptide stimulating an enhanced immune response 
(6). Subsequent findings in various other experimental systems 
reiterated these seminal findings of Solinger et  al. that certain 
peptide variants can restimulate more potent immune responses 
than the native, WT, reference or index peptide epitopes the 
immune system was actually exposed to (4, 7–14). In this review, 
we will focus on the possible utility of heteroclitic peptides for 
immunotherapy of human immunodeficiency virus (HIV) 
infection.
Heteroclitic Peptides Augment and 
Modulate T Cell Cytokine Production
Cytokines play a significant role in orchestrating T cell devel-
opment, differentiation, effector functions, and survival (15). 
Several experimental models have shown that heteroclitic 
peptides can enhance T cell cytokine responses beyond those 
stimulated by native peptides (4, 16–18). In 1997, Tao et al. dem-
onstrated that heteroclitic peptide stimulation of CD4+ T cells 
in vitro significantly increased production of both interleukin-4 
(IL-4) and interferon-gamma (IFN-γ), compared to stimulation 
with WT peptides (19). Salazar et  al. found that a heteroclitic 
variant (CAP1-6D) of an immunodominant human carcinoem-
bryonic antigen (CEA)-specific CD8+ T cell epitope (CAP1; 
YLSGANLNL) triggered a 1,000-fold increase in granulocyte-
macrophage colony-stimulating factor (GM-CSF) and IFN-γ 
over the levels induced by CAP1 (4). In chronic infections such 
as HIV, development of antigen-specific T cell dysfunction, 
or exhaustion, is often reflected in sequential loss of cytokine 
production capacity, first with reduced ability to produce IL-2 
followed by tumor necrosis factor-alpha (TNF-α) and lastly, loss 
of IFN-γ production (20–22). Variants of immunodominant HIV 
Gag and Nef epitopes tested in vitro by Gladney et al. enhanced 
IFN-γ and/or interleukin-2 (IL-2) production by HIV-specific 
CD8+ T cells compared to stimulation with the reference pep-
tides, demonstrating heteroclitic properties in the context of 
cytokine modulation (23). In some cases, the effects were purely 
quantitative with an increased number of cells producing IFN-γ, 
IL-2, or both, but there were also cases where variant peptides 
selectively skewed cytokine production toward IL-2 (23). Thus, 
in settings where chronic infection leads to T cell exhaustion, the 
heteroclitic capacity of variant peptides may enhance nominal 
T cell functions or even reconstitute T cell functions no longer 
stimulated by native peptide epitopes. In follow-up experiments, 
additional heteroclitic-HIV peptides that stimulated larger 
cytokine responses, as reported by Gladney et al., were identified 
and then tested for their ability to increase T cell proliferation 
and reduce phenotypic evidence of exhaustion relative to in vitro 
stimulation with native peptides (24).
Heteroclitic Peptides enhance T Cell 
Proliferation
Failure to contain tumor growth is partly attributed to suboptimal 
proliferation of tumor-specific T cells responding against poorly 
immunogenic tumor-associated antigens (TAA) (25). To circum-
vent this issue, heteroclitic peptide variants of TAA were used 
to expand naïve TAA-reactive T cells and generate more effec-
tive antitumor T cell responses (26–28). In certain cases, more 
powerful adjuvants can also be used to overcome the relative 
immune tolerance to TAA or the relatively weak binding of self-
peptides to HLA molecules (29). Another example of heteroclitic 
peptides enhancing T cell proliferation was in  vitro expansion 
of T cells using an analog of an autoantigenic peptide 139–151 
(HSLGKWLGHPDKF) from myelin proteolipid protein (PLP) in 
which tryptophan (W) was replaced by glutamine (Q) at position 
144 (30). While the first case leads to an enhanced anti-tumor 
response and the second promotes autoimmunity, the same 
principle is illustrated in that weak T cell responses, due in part to 
self-tolerance, can be invigorated using heteroclitic stimulation. 
In chronic HIV infection, reduced proliferation of HIV-specific 
T cells with progressive infection reflects T cell exhaustion, which 
while distinct from anergy due to self-tolerance may be modu-
lated through the same approach. We found that heteroclitic HIV 
peptide stimulation increased HIV-specific CD8+ T cell prolifera-
tion by at least 20%, and up to 1100% relative to reference peptide 
stimulation for nearly 50% of the heteroclitic/reference peptide 
pairs we compared (24).
Heteroclitic Peptides Activate T Cells  
with High Avidity
Functional avidity is a measure of the amount of antigenic peptide 
required to successfully activate or trigger the effector functions 
of activated T cells (31, 32). Those T cells that respond efficiently 
at low doses of antigen are called high-avidity T cells (33). Several 
studies indicate a strong correlation between pMHC:TCR stabil-
ity and functional T cell avidity (34–36). The enhanced anti-
tumor cell-mediated immunity associated with loss of tolerance 
to TAA in studies using heteroclitic TAA peptides was due to 
increased pMHC:TCR stability of the heteroclitic peptides, 
reflected in higher avidity and longer interaction times (8, 13, 
28, 37). Similar effects were observed when the Mycoplasma 
penetrans HF-2 (MPHF2) permease protein-derived peptide 
(IYIFAACL) was used to stimulate melanoma antigen gene 
(MAGE)-A6-reactive CD4+ T cells (38). The functional avidity of 
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MAGE-A6-reactive CD4+ T cells stimulated with MPHF2 peptide 
was approximately 1000 times greater than that of MAGE-A6-
specific CD4+ T cells stimulated with the WT MAGE-A6 peptide 
(IGHVYIFATCLGLSYD) (38). While the absolute number of 
HIV-specific CD8+ T cells recruited during primary HIV infec-
tion is undoubtedly important, HIV-specific CD8+ cells with 
high-avidity for HIV peptide epitopes are key to early HIV sup-
pression (39–42). In contrast to the well-documented examples 
of heteroclitic TAA peptides inducing high-avidity T cells, there 
has been limited study of high-avidity T cell generation using 
heteroclitic peptides in the context of HIV infection. Stimulation 
with heteroclitic variants of an HIV-reverse transcriptase (RT) 
peptide (residues 309–317) significantly increased cytotoxic T 
lymphocyte (CTL) responses against the native pol peptide in 
all donors tested in comparison to stimulation with the native 
pol peptide (43, 44). A threefold increase in levels of the HLA-
A*0201-peptide complex on the surface of antigen-presenting 
cells (APC) pulsed with the heteroclitic variants was thought to 
underlie the enhanced CTL responses (43, 44). Another study 
suggested that HIV protease (PR) peptide 76–84 (LVGPTPVNI), 
acting as a heteroclitic variant of IFN-γ-inducible protein 30 (IP-
30) signal peptide −11 to −3 (LLDVPTAAV), activates autoreac-
tive T cells in a subset of HIV-1-infected individuals expressing 
HLA-A2 (45, 46). Therefore, exposure to heteroclitic peptides 
can potentially cut both ways with promotion of autoimmunity 
through the activation of self-reactive T cells an equally possible 
outcome as enhancement of T cell responses against foreign or 
tumor antigens.
Heteroclitic Peptides enhance  
CTL Activity
Recognition and killing of infected cells is an important immu-
nological effector function against HIV and other viruses and the 
critical importance of HIV-specific CTL in controlling viremia is 
well documented (35, 36). The ability to upregulate production 
of cytotoxins (perforin and granzymes) and to degranulate in a 
manner releasing them toward target cells is associated with viral 
control in long-term non-progressors (LTNP) and, conversely, 
is usually impaired in rapid progressors (RP) (47–49). Cytolysis 
of target cells by CTL can also be mediated through the Fas-Fas 
ligand (FasL) pathway, but perforin–granzyme release through 
degranulation is thought to be the predominant mode of killing 
of infected target cells by HIV-specific CTL (47). Several analogs 
of the HIV (RT) peptide ILKEPVHGV were tested for their 
ability to enhance HIV pol-specific CTL activity. Stimulation 
of peripheral blood mononuclear cells from HIV-infected indi-
viduals in vitro with I1→Y and I1→F variant peptides generated 
significantly higher WT pol-specific CTL activity compared 
to stimulation with the WT pol peptide (ILKEPVHGV) (43, 
44). Likewise, for a series of subjects with chronic lymphocytic 
leukemia (CLL), CTL that were generated by stimulation with 
the heteroclitic immunoglobulin (Ig) variable gene framework 
region (FR)-derived peptide (QLPGKGLEWV) had enhanced 
cytotoxicity against APC pulsed with the native peptide (FR-18; 
QAPGKGLEWV) and killed CLL cells, but not unpulsed, CD40-
activated APC (13, 50, 51). In another example, CTL raised by 
stimulation with a heteroclitic FR-9 peptide (KLFLQMNSL) 
effectively lysed APC pulsed with the heteroclitic peptide and 
CLL cells displaying the native epitope (FR-9; TLFLQMNSL), 
while CTL generated by stimulation with the native peptide FR-9 
failed to lyse either APC stimulated with the native peptide or 
FR-9-positive CLL cells (51). In a separate study, heteroclitic-
variants of CD33, a cell surface glycoprotein restricted to 
myeloid lineage cells, effectively generated acute myeloid 
leukemia (AML)-specific CTL, that did not lyse or inhibit the 
proliferation of normal CD34+ progenitor cells (11, 12). These 
findings indicate that heteroclitic peptide stimulation often can 
generate substantially more effective CTL responses than the 
native epitopes. In certain  situations, they can even activate 
autoreactive T cells in such a way that allows selective killing of 
infected or transformed cells over normal healthy cells. Induction 
of stronger, more durable, higher avidity T cell responses could 
be a powerful aspect of preventive and therapeutic HIV vaccines 
incorporating heteroclitic peptides.
Heteroclitic Peptides induce Less 
evidence of T Cell exhaustion
In HIV infection, chronic expression of programed death-1 (PD-
1) molecules on HIV-specific T cells is a signature of functional T 
cell impairment that is clearly associated with disease progression 
(52–55). The HIV-specific CD8+ T cells of elite controllers (EC) 
and LTNP express significantly less PD-1 than those of normal 
or fast progressors (56). Several studies aimed at improving 
exhausted T cell responses used monoclonal antibodies to block 
either PD-1 or its ligands or introduced exogenous costimulatory 
molecules such as 4-1BB. In each case, the intervention improved 
the effector functions of responding T cells to some extent (53, 
57). However, native HIV-peptide epitopes were used to stimulate 
HIV-specific CD8+ T cells in these instances, suggesting that 
even more benefit might be derived using heteroclitic peptides. 
A recent study demonstrated that heteroclitic variants of native 
HIV-peptide epitopes can improve the character as well as the 
magnitude of HIV-specific CD8+ T cell responses relative to 
responses induced by reference epitopes, even without introduc-
ing exogenous costimulatory molecules or blocking inhibitory 
receptors. In approximately 50% of cases tested, the fraction of 
proliferating HIV-specific CD8+ T cells expressing PD-1 was 
significantly reduced (by 15–88%) following stimulation with 
heteroclitic peptides in comparison to stimulation with reference 
peptides (24). While the effect of heteroclitic peptide stimulation 
on expression of T cell exhaustion markers was not studied in the 
other experimental systems cited, it is possible that the improved 
T cell responses were at least partially related to reduced exhaus-
tion of the stimulated T cells.
Surprisingly, there was no significant correlation between 
reduced PD-1 expression and enhanced proliferation in experi-
ments carried out with heteroclitic peptides. This could mean 
either that heteroclitic peptides select for distinct heterogeneous 
subsets of HIV-specific CD8+ T cells or that activation signals 
generated by heteroclitic peptide stimulation can somehow 
bypass the PD-1 signaling pathway, thereby allowing enhanced 
proliferation even of PD-1hi CD8+ T cells (Figure 1). Normally, 
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inhibitory signals delivered by PD-1 downregulate TCR signal-
ing through direct dephosphorylation of intracellular signaling 
intermediates. The phosphatases associated with PD-1 (SHP-1 
and SHP-2) dephosphorylate CD3ζ and prevent phosphoryla-
tion of ZAP-70 and PKCθ (58). A possible explanation for the 
negligible effects of PD-1 signaling on proliferating HIV-specific 
CD8+ T cells responding to heteroclitic peptide stimulation could 
FiGURe 1 | Differential activation of Hiv-specific CD8+ T cells by native 
and heteroclitic peptides. (A) HIV-specific CD8+ T cell stimulation with 
HIV-1 native peptide epitopes increases PD-1 expression. PD-1 ligation with 
its ligand (PD-L) causes immediate phosphorylation of the immunoreceptor 
tyrosine-based inhibitory motifs (ITIM) and immunoreceptor tyrosine-based 
switch motifs (ITSM). Recruitment of SHP-2 to the tyrosine residues 
associated with PD-1 dephosphorylates TCR ζ chains, downregulates TCR 
signaling, and prevents the phosphorylation of ZAP-70. (B) Heteroclitic 
peptide stimulation increases tyrosine phosphorylation of ZAP-70 and TCR ζ 
chains, and also downregulates PD-1 expression on responding T cells 
(downregulated PD-1 is shown in dotted lines). Signals generated by 
heteroclitic peptide stimulation through the TCR somehow bypass the PD-1 
signaling pathway; thereby improving T cell responses. (C) Heteroclitic 
peptide stimulation selectively activates a different subset of HIV-specific 
CD8+ T cells that express less PD-1 than the CD8+ T cells responding to the 
native peptide.
be increased tyrosine phosphorylation of ZAP-70 and TCR ζ 
chains in CTL stimulated with heteroclitic peptides relative to 
native peptide-stimulated CTL. In fact, this was reported in the 
study by Salazar et al. and supports the possibility that heteroclitic 
peptides can potentially bypass the pathways effecting exhaustion 
when stimulation with reference peptides occurs (4). A more 
recent publication demonstrated differential effects on the PD-1 
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expression of HIV-specific CD8+ T cells in relation to their TCR 
clonotype as well as epitope specificity and in  vivo history of 
antigenic exposure (59). Thus, a variety of intrinsic and extrinsic 
factors can modulate translation of T cell stimulation by even 
closely related peptides into a range of potential outcomes.
Heteroclitic Peptides for “Kick and Kill” 
Approaches to Purge the Hiv Reservoir
Despite the spectacular success of combination antiretroviral 
therapy (cART) in treating HIV infection, it remains impos-
sible to cure HIV infection in all but extremely rare cases. Cure 
could either be sterilizing, with eradication of all HIV-infected 
cells and infectious viral particles, or functional, with long-term 
suppression of HIV replication in the absence of cART (60). The 
“Berlin patient,” who was transplanted with allogeneic stem cells 
from a CCR5 delta32-homozygous donor, is regarded as the only 
documented case of sterilizing cure (61–63). Other reported 
cases of HIV cure upon cART cessation such as the VISCONTI 
cohort and the “Mississippi baby” represented functional cures 
with unknown, and as we now know, questionable durability 
(64–68). Viral rebound in individuals taken off treatment or 
once classified as “functionally cured” is attributed to the long-
lived HIV reservoir persisting in latently infected cells (69). An 
approach to HIV cure termed the “kick and kill” strategy has been 
developed to overcome the challenges posed by this long-lived 
HIV reservoir. This approach aims to reactivate latent viruses 
with histone deacetylase inhibitors and other agents (the “kick”) 
and then expose the reactivated viruses and infected cells to HIV-
specific immunity and/or cART (the “kill”) (70). Concerns have 
been raised as to the capacity of endogenous CTL to recognize 
and mediate their effector functions with the efficacy required to 
extinguish reactivated HIV (71). Sung et al. showed that in vitro 
restimulation and expansion of endogenous anti-HIV CTL 
produced effector cells targeting the latent reservoir (72). Either 
in vivo or in vitro restimulation of anti-HIV CTL with defined 
heteroclitic peptides in concert with the kick approach to reacti-
vate latent virus from the reservoir could enhance the capacity of 
anti-HIV CTL to effectively target reactivated virus.
The potential for heteroclitic peptides to generate higher 
avidity cross-reactive CTL to help purge escape variants that 
significantly contribute to residual viremia was previously 
documented in murine hepatitis virus (MHV) infection (73). 
Two MHV strain JHM (JHMV)-derived CTL epitopes, S510 
(CSLWNGPHL) and S598 (RCQIFANI), were shown to induce 
very high- and low-magnitude T cell responses, respectively, 
that select for escape mutants during chronic MHV-infection 
in C57BL/6 (B6) mice. The immunodominant epitope, S510, 
generates high-avidity CTL responses; whereas an approximately 
100-fold lower avidity T cell response is generated against the 
subdominant epitope, S598. To improve CD8+ T cell responses 
against S598, Butler et  al. substituted a tyrosine residue for 
glutamine at position 3 of the S598 peptide sequence (Q600Y; 
RCYIFANI). Approximately, 100-fold more native S598 peptide 
is required to reach the response level induced by the heteroclitic 
Q600Y peptide. Immunization with Q600Y effectively protected 
against disease progression in the context of both S598 and S510 
CTL escape mutations, and enhanced clearance of MHV (74). 
Thus, heteroclitic peptides could be effective against CTL escape 
in chronic HIV infection and also be beneficial in the “kick and 
kill” approach to HIV cure.
Heteroclitic Peptides and Hiv 
immunotherapy
Unlike prophylactic vaccines, which provide uninfected persons 
protection against invading pathogens, therapeutic (treatment) 
vaccines are designed to modulate the ongoing immune response 
in unresolved infections or other chronic conditions. Therapeutic 
vaccines are generally engineered to induce cell-mediated, rather 
than humoral immunity by enhancing existing or generating 
new immune responses toward chronic pathogens or tumor 
antigens. While most HIV-infected individuals have strong CTL 
responses in the primary phase of infection, chronic infection 
ensues at least in part due to the ability of the virus to escape 
effective recognition by HIV-specific CD8+ T cells (75). Thus, 
viral persistence, reflecting inefficient recognition of HIV escape 
mutants, precedes the functional impairment of HIV-specific T 
cells (22). Although cART has dramatically reduced morbidity 
and mortality among individuals with chronic HIV infection, 
HIV-specific CD8+ T cell dysfunction persists through successful 
ART treatment, leaving the immune system in a compromised 
state (76, 77). In addition, the high cost, pill burden, requirement 
for strict adherence, and side effects are all drawbacks that limit 
universal application of cART to contain the HIV epidemic. The 
economic burden imposed by the HIV epidemic in both the 
developing and developed world has already hindered growth. 
For economic reasons alone, there is an urgent need to explore 
alternatives to cART, such as immune-based strategies that can 
reduce the requirement for life-time cART and ease associated 
physiological and economic burdens.
Potentially heteroclitic variants were previously generated 
using HLA-A2 and A3-restricted tumor-associated peptides 
(9mers and 10mers), an HLA-A2-restricted hepatitis B virus 
(HBV) peptide, Pol.455 and HIV Pol.476 (both 9mers). 
Regardless of their length, variant peptides with heteroclitic 
activity all had either conservative or semiconservative aa 
substitutions at positions 3, 5, or 7 and decreased the amount of 
peptide required to trigger T cell responses by up to 107-fold (37). 
Inferred 3D structures from X-ray crystallography of HLA-A2 
and A3 pMHC:TCR complexes revealed that the side chains of 
aa at positions 3, 5, and 7 of these peptides bound to the MHC 
molecules interact directly with complementarity determining 
region 3 (CDR3) of the TCR α and β chains (78, 79). A table of 
aa similarity scores used in this study by Sette et al. was derived 
by averaging the rank coefficient score for tolerability of point 
mutations within a protein as estimated by the Dayhoff point 
accepted mutation (PAM) matrix 250, hydrophobicity calculated 
from the average of Kyte/Doolittle and Fauchere/Pliska scales 
estimating hydrophobicity and hydrophilicity, respectively, and 
aa side chain volume (measured by H2O displacement) for each 
aa pair (37). It was later shown that heteroclitic variants of HIV 
native peptide epitopes can be generated in a manner similar 
to that illustrated by Sette et  al. using the same table to select 
TABLe 1 | Native peptides and heteroclitic variants cited.
Native peptide Heteroclitic variant Reference
Pigeon cytochrome c Tobacco hornworm moth 
cytochrome c
(6)
CAP1; YLSGANLNL CAP1-6D; YLSGADLNL (4)
PLP 139-151; 
HSLGKWLGHPDDF
PLP 139-151, W144Q; 
HSLGKQLGHPDDF
(29)
MAGE-A6; IGHVYIFATCLGLSYD MPFH2; iYIFAACL (37)
IP-30 -11 to -3; LLDVPTAAV HIV PR 76-84; LvGPTPvNi (44)
HIV RT 309-317; ILKEPVHGV HIV RT 309-317, I1Y; 
YLKEPVHGV
(42)
HIV RT 309-317; ILKEPVHGV HIV RT 309-317, I1F; 
FLKEPVHGV
(42)
FR-18; QAPGKGLEWV FR-18; QLPGKGLEWV (13)
FR-9; TLFLQMNSL FR-9; KLFLQMNSL (50)
S598; RCQIFANI S598, Q600Y; RCYIFANI (72)
Melan-A EAAGIGILTV Melan-A ELAGIGILTV (28)
Native peptides and heteroclitic variants cited as examples in the text are tabulated 
together with the corresponding reference. Although nomenclature used is not always 
standard, the peptide sequence is generally preceded by an abbreviation indicating the 
source and protein name followed by aa sequence coordinates within that protein, site, 
and identity of the relevant aa substitution in the heteroclitic variant and the peptide 
sequence. Altered amino acids within the heteroclitic variant are shown in bold text.
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conservative and semi-conservative aa substitutions at positions 
3, 5, and 7 of native peptide epitopes (23).
Design and Testing of Heteroclitic Peptide 
vaccines for Hiv
Potential barriers to developing generalized heteroclitic peptides 
for therapeutic vaccination against HIV include inherent indi-
vidual diversity in HLA class I genotypes and TCR repertoires 
plus differential immunological responsiveness reflecting the 
variable impact of HIV infection itself. Our experience has been 
that HIV-infected individuals responding against the same WT 
peptide often do not demonstrate heteroclitic responses against 
the same variant peptides (23). Thus, heteroclitic peptide vaccines 
would need to be individually designed, at least initially. While not 
an optimal approach to vaccination, the overall investment is not 
prohibitive compared to drug resistance and viral tropism testing 
or when considered in terms of the potential to reduce antiretro-
viral dependence or contribute to HIV cure. Individuals would 
require mapping of their HIV-specific CD8+ T cell responses by 
standard methods first with available overlapping peptide pools 
and subsequently with deconvoluting matrices (23). Epitopes 
would be selected for further investigation from amongst those 
identified based on immunodominance and polyfunctionality of 
the responding T cells in terms of their cytokine production. The 
semi-systematic approach to generating candidate heteroclitic 
peptides by making conservative and semi-conservative aa sub-
stitutions at positions 3, 5, and 7 can probably be improved using 
population-based HIV sequence data sorted by HLA genotype. 
Analysis of such data indicates sites of immune selection with 
an estimable hierarchy and identifies putative adapted (escape) 
mutations and, more importantly, non-adapted or excluded aa at 
particular sites within CTL epitopes that are likely excluded due 
to enhanced immunogenicity of that sequence (80). Although it 
seems counterintuitive, it may be exactly these sequences selec-
tively avoided by HIV in the context of certain HLA molecules, 
rather than broadly conserved sequences, that are the most effec-
tive immunogens against HIV. Large series of variant peptides 
for those epitopes most common in the population could be syn-
thesized and tested in vitro for heteroclitic properties. The ideal 
heteroclitic peptide should activate a higher fraction of CD8+ T 
cells, stimulate a more polyfunctional response, increase CD8+ 
T cell proliferation, and drive differentiation of fully functional 
effector cells with equal or superior TCR recognition of the native 
peptides and existing variants. Individual in vitro testing for het-
eroclitic function reduces the risk that administered peptides will 
have partial agonist or antagonist functions that actually impair 
the CD8+ T cell response against HIV in vivo. Higher frequency 
in vitro responses do not necessarily translate into more effective 
responses in vivo. Vaccination with a heteroclitic peptide deriva-
tive (ELAGIGILTV) of Melan-A (EAAGIGILTV), which had 
higher affinity to HLA, induced twice the frequency of peptide-
reactive T cells as vaccination with the natural peptide. However, 
analysis of responding T cells at the clonal level indicated a 
marked preference for recognition of the heteroclitic peptide 
over the natural peptide with recognition at lower peptide con-
centrations due to the increased affinity for HLA (28). Thus, TCR 
recognition efficacy may be overestimated in terms of the ability 
to mediate effector functions against target cells presenting the 
natural peptide. Choosing heteroclitic peptides with aa modifica-
tions at TCR interaction sites not affecting HLA-binding affinity 
may allow for more unbiased comparison of TCR recognition 
efficiency in vitro. The risk of activating autoreactive T cells must 
be measured against the potential benefits of heteroclitic vaccina-
tion in HIV infection. It is impossible to comprehensively test for 
autoreactivity against all self-antigens presented to CD8+ T cells 
using cells available from peripheral blood, but autoreactivity 
could also be tested against broad panels of cell lines express-
ing the same HLA class I antigen that presents the heteroclitic 
peptide variants identified. If more than one suitable heteroclitic 
peptide were identified, they could be administered individually, 
together or as a long synthetic peptide by subcutaneous injec-
tion with an approved adjuvant. Subjects would be monitored 
for an enhanced CD8+ T cell response against HIV following 
vaccination.
Conclusion
The purpose of this review was to highlight the potential advan-
tages of incorporating heteroclitic peptides into therapeutic vac-
cines, in particular into therapeutic HIV vaccines. Heteroclitic 
peptide stimulation has been shown to produce beneficial immune 
responses in a number of chronic infections and disease models 
(Table 1). Changes as subtle as a single conservative aa substitu-
tion within the native peptide epitope sequence can improve T 
cell responses in the form of enhanced cytokine production and 
increased proliferation. This can also produce higher-avidity T 
cell responses, more effective CTL killing, protection against CTL 
escape, elimination of chronic infection, specific abrogation of 
self-tolerance that elicits anti-tumor immunity, and prevention 
or reversal of T cell exhaustion. As with other peptide-based 
July 2015 | Volume 6 | Article 3777
Adegoke and Grant Enhancing CD8+ T cell responses
Frontiers in Immunology | www.frontiersin.org
vaccines, heteroclitic peptide immunotherapy poses no risk of 
genetic integration or recombination, as with DNA vaccines, 
and no risk of developing virulent reassortants or of reversion to 
virulent (WT) viruses as with attenuated virus vaccines. Hence, 
administration of heteroclitic peptides is an exceptionally safe, 
potentially effective mode of vaccination. Heteroclitic peptide-
based vaccines could be commercially produced on a large scale 
at low cost, affording those poor nations most plagued by the HIV 
epidemic the potential benefits of immunotherapy. Heteroclitic 
peptide vaccine formulations can also be stored in lyophilized 
form, thereby avoiding the need for “cold-chain” maintenance 
during storage, transport, and distribution. Consequently, they 
can be made readily available to the most remote and intem-
perate locations. The many demonstrated practical and theo-
retical advantages of heteroclitic peptides suggest that more 
research on their inclusion into therapeutic HIV vaccines is 
warranted.
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